Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit Impact On Pharmacovigilance Depends On UK MHRA’s Access To EU Databases And Systems

Executive Summary

The UK’s current oversight of pharmacovigilance systems is dependent on its access to several databases and centralized systems designed to serve the single EU market. If the UK cannot have continued access to these systems post Brexit, companies may face duplicative requirements and greater workload.

You may also be interested in...



Modernized Pharmacovigilance Database Nears In Switzerland

Switzerland is on track with plans to adopt a new modernized pharmacovigilance system with enhanced data analysis capabilities. The new system will not result in any changes to how companies and healthcare professionals report adverse drug reactions to Swissmedic.

Swissmedic kicks off pharmacovigilance database modernization plans

Switzerland’s healthcare product regulator, Swissmedic, is planning to replace the pharmacovigilance database it currently uses with a modern system by the end of 2017 and has issued a request for information on the project from software suppliers1.

New Canadian Rule Allows Rolling Data Submissions For COVID-19 Drugs, Vaccines

The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel